Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
From a metabolic perspective, cancer may be considered as a metabolic disease characterized by reprogrammed glycolytic metabolism. The aim of the present study was to investigate
CD147
-mediated glucose metabolic regulation in
hepatocellular carcinoma
(
HCC
) and its contribution to altered immune responses in the tumor microenvironment. Several
HCC
cell lines and corresponding nude mice xenografts models differing in
CD147
expressions were established to directly investigate the role of
CD147
in the reprogramming of glucose metabolism, and to determine the underlying molecular mechanisms. Immunohistochemistry (IHC) analyses and flow cytometry were used to identify the relationship between reprogrammed glycolysis and immunosuppression in
HCC
. Upregulated
CD147
expressions were found to be associated with enhanced expressions of GLUT1, MCT1 in
HCC
tumorous tissues.
CD147
promoted the glycolytic metabolism in
HCC
cell lines in vitro via the PI3K/Akt/mTOR signaling pathway. A positive correlation existed between a profile of immunosuppressive lymphocytes infiltration and
CD147
expression in
HCC
tissues. Accumulation of FOXP3-expressing regulatory T cells was induced under a stimulation with lactate in vitro. In conclusion,
CD147
promoted glycolytic metabolism in
HCC
via the PI3K/Akt/mTOR signaling pathway, and was related to immunosuppression in
HCC
.
...
PMID:Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma. 3196 68
It is reported that long noncoding RNA RHPN1-AS1 (lncRNA RHPN1-AS1) functions as an oncogene among multiple types of cancers; however, the effect of lncRNA RHPN1-AS1 in
hepatocellular carcinoma
(
HCC
) is left to be investigated. The main purpose of this work was to study the effects of lncRNA RHPN1-AS1/miR-485-5p system on proliferation, migration, and invasion in
HCC
and future investigate the latent mechanisms. Our work found that lncRNA RHPN1-AS1 was observably up-regulated in
HCC
tissues and cell lines, especially HCCLM3 and SMMC-7721 cells. LncRNA RHPN1-AS1 knockdown decreased the capacity of proliferation, invasion, and migration in HCCLM3 and SMMC-7721 cells, which could be crippled by miR-485-5p inhibitor. Besides, the expression of
basigin
(
BSG
) was decreased after lncRNA RHPN1-AS1 silence, indicating the function of lncRNA RHPN1-AS1/miR-485-5p/
BSG
axis in
HCC
progression. Our study opens novel insights to help understand the mechanisms of lncRNA RHPN1-AS1/miR-485-5p/
BSG
axis in
HCC
progression, which may provide a new therapeutic target for
HCC
treatment.
...
PMID:LncRNA RHPN1-AS1 accelerates proliferation, migration, and invasion via regulating miR-485-5p/BSG axis in hepatocellular carcinoma. 3243 75
Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for treating multiple refractory blood cancers, but further advances are required for solid tumor CAR therapy. One challenge is identifying a safe and effective tumor antigen. Here, we devise a strategy for targeting
hepatocellular carcinoma
(
HCC
, one of the deadliest malignancies). We report that T and NK cells transduced with a CAR that recognizes the surface marker,
CD147
, also known as Basigin, can effectively kill various malignant
HCC
cell lines in vitro, and
HCC
tumors in xenograft and patient-derived xenograft mouse models. To minimize any on-target/off-tumor toxicity, we use logic-gated (log) GPC3-synNotch-inducible
CD147
-CAR to target
HCC
. LogCD147-CAR selectively kills dual antigen (GPC3
+
CD147
+
), but not single antigen (GPC3
-
CD147
+
) positive
HCC
cells and does not cause severe on-target/off-tumor toxicity in a human
CD147
transgenic mouse model. In conclusion, these findings support the therapeutic potential of
CD147
-CAR-modified immune cells for
HCC
patients.
...
PMID:Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. 3296 61
<< Previous
1
2
3
4
5
6
7
8
9